Similarly, the high density of CD3+, CD8+ and granzyme B+ lymphocytes in the invasive margin of hepatic CRC metastases was predictive of prolonged disease-free survival in patients treated with conventional chemotherapy or chemotherapy in combination with cetuximab or bevacizumab (126). This evidence concerns the gene CD8A and colorectal carcinoma.